<DOC>
	<DOCNO>NCT00470405</DOCNO>
	<brief_summary>RATIONALE : Pemetrexed may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy , oxaliplatin , work different way stop growth cancer cell , either kill cell stop divide . Giving pemetrexed together oxaliplatin may kill cancer cell . PURPOSE : This phase I trial study side effect best dose pemetrexed give together oxaliplatin treat patient metastatic solid tumor lymphoma .</brief_summary>
	<brief_title>Pemetrexed Oxaliplatin Treating Patients With Metastatic Solid Tumors Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose recommended phase II dose pemetrexed disodium combination oxaliplatin patient metastatic solid tumor lymphoma . Secondary - Determine quantitative qualitative toxicity regimen patient . - Determine , preliminarily , efficacy regimen patient . OUTLINE : This dose-escalation study . Patients receive pemetrexed disodium IV 10 minute oxaliplatin IV 2 hour day 1 . Treatment repeat every 14 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos pemetrexed disodium oxaliplatin maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Once MTD determine , recommend phase II dose identify . After completion study treatment , patient follow 30 day periodically thereafter . PROJECTED ACCRUAL : A total 36 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Pathologic cytologic diagnosis solid tumor lymphoma Metastatic disease No curative effective therapy exist Measurable nonmeasurable disease No clinically relevant thirdspace fluid collection Fluid collection must drain study enrollment No leukemia No CNS metastases ECOG performance status 02 Life expectancy ≥ 12 week ANC ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9 g/dL Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ALT ≤ 3.0 time ULN ( 5 time ULN liver tumor involvement ) Creatinine clearance ≥ 45 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month completion study therapy No active infection serious illness would preclude study participation No weight loss ≥ 10 % within past 6 week No peripheral neuropathy ( e.g. , diabetic neuropathy ) ≥ CTC grade 1 Must able take concurrent vitamin B12 folic acid PRIOR CONCURRENT THERAPY : No 1 prior chemotherapy regimen metastatic disease More 12 month since prior adjuvant therapy More 30 day since prior drug receive regulatory approval More 30 day since prior radiation therapy recover ( alopecia allow ) Prior standard postoperative adjuvant radiation therapy rectal cancer allow No prior radiation therapy ≥ 25 % bone marrow No prior oxaliplatin pemetrexed disodium No NSAIDs acetylsalicylic acid 2 day ( 5 day longacting agent [ e.g. , piroxicam ] ) , , 2 day dose pemetrexed disodium No concurrent nonpalliative radiation therapy surgery cancer No concurrent hormonal cancer therapy ( except medroxyprogesterone ) No concurrent experimental medication ( except thymidine ) No concurrent chemotherapy immunotherapy No concurrent anticancer therapy Concurrent palliative radiation therapy allow small area painful metastasis manage adequately systemic local analgesic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>adult solid tumor</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>cutaneous B-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
</DOC>